Ondansetron | 5-HT₃ Antagonist | CAS 99614-02-5 | Anti-emetic API
Product Name: Ondansetron
CAS No.: 99614-02-5
Molecular Formula: C₁₈H₁₉N₃O
Appearance: White or almost white crystalline powder
Solubility: Sparingly soluble in water; soluble in methanol and ethanol. For parenteral administration, often used as hydrochloride dihydrate (more water-soluble).
Stability: Stable when stored protected from light
1. Introduction
Ondansetron is a selective 5-HT₃ serotonin receptor antagonist widely used as an anti-emetic. It is effective for the prevention and treatment of nausea and vomiting caused by chemotherapy, radiation therapy, and postoperative nausea and vomiting.
Nausea and vomiting are common and poorly tolerated side effects of anticancer therapy and surgical interventions. Ondansetron was one of the first and most successful drugs of the setron class, significantly improving the quality of life for patients undergoing such treatments. Its mechanism of action involves blocking 5-HT₃ receptors both in the central nervous system (chemoreceptor trigger zone) and peripherally (gastrointestinal tract).
2. Chemical Structure & Synthesis
Ondansetron is a carbazole derivative.
Molecular Formula: C₁₈H₁₉N₃O
The synthesis of ondansetron involves several steps, starting from carbazole derivatives followed by the introduction of an imidazole ring and a methyl group. The process requires precise control of reaction conditions to ensure high purity and yield.
3. Physicochemical Properties
| Property | Description |
|---|---|
| Appearance | White or almost white crystalline powder |
| Solubility | Sparingly soluble in water; soluble in methanol and ethanol |
| Stability | Stable when stored protected from light |
| Pharmacokinetics | Well absorbed orally; extensive hepatic metabolism (cytochrome P450); excreted in urine and feces as metabolites and unchanged drug |
4. Applications
| Indication | Use |
|---|---|
| Chemotherapy-Induced Nausea & Vomiting (CINV) | Standard of care for preventing emetic effects of many anticancer drugs |
| Radiation-Induced Nausea & Vomiting (RINV) | Effective for irradiation of emetogenic areas |
| Postoperative Nausea & Vomiting (PONV) | Widely used in anesthesiology to reduce PONV incidence |
5. Conclusion
Ondansetron revolutionized the treatment of nausea and vomiting associated with cancer treatment and surgical interventions. Its high efficacy and relatively good tolerability profile have made it the gold standard in anti-emetic therapy. Further research is focused on exploring its use in other conditions accompanied by nausea and vomiting, as well as the development of new drugs in this class with improved properties.
